[Federal Register Volume 64, Number 109 (Tuesday, June 8, 1999)]
[Notices]
[Pages 30526-30527]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-14406]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
National Mammography Quality Assurance Advisory Committee; Notice
of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
[[Page 30527]]
Name of Committee: National Mammography Quality Assurance Advisory
Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on July 12, 1999, 9 a.m. to
6 p.m.
Location: Hilton Hotel, Salons A and B, 620 Perry Pkwy.,
Gaithersburg, MD.
Contact Person: Charles A. Finder, Center for Devices and
Radiological Health (HFZ-240), Food and Drug Administration, 1350
Piccard Dr., Rockville, MD 20850, 301-594-3332, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), code 12397. Please call the Information Line for
up-to-date information on this meeting.
Agenda: The committee will discuss problematic issues encountered
during the early phases of implementation of the final regulations and
continue the discussion of the proposed Mammography Quality Standards
Act (MQSA) compliance guidance. This guidance is being updated
continually in response to questions that FDA receives from the public.
The committee will also receive updates on the issues of States as
Certifying Bodies under MQSA and Voluntary Stereotactic Accreditation
Programs. The draft MQSA compliance guidance documents, which are in a
question and answer format, are available to the public on the Internet
at ``http://www.fda.gov/cdrh/dmqrp/guidance.html''. Additional
information regarding guidance updates may be obtained by calling the
Information Line.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by June 14, 1999.
Oral presentations from the public will be scheduled between
approximately 9:30 a.m. and 10:30 a.m. Time allotted for each
presentation may be limited. Those desiring to make formal oral
presentations should notify the contact person before June 14, 1999,
and submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: May 28, 1999.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 99-14406 Filed 6-7-99; 8:45 am]
BILLING CODE 4160-01-F
